Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease. (2nd August 2021)

• Record Type: Journal Article
• Authors: Svetnik, Vladimir; Wang, Ting‐Chuan; Ceesay, Paulette; Snyder, Ellen; Ceren, Omar; Bliwise, Donald; Budd, Kerry; Hutzelmann, Jill; Stevens, Joanne; Lines, Christopher; Michelson, David; Herring, W. Joseph
• Is Part Of: Journal of sleep research. Volume 30:Number 6(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-08-02
• Subjects: actigraphy -- Alzheimer's disease -- insomnia -- polysomnography -- randomized clinical trial -- suvorexant; Sleep -- Periodicals; Sleep disorders -- Periodicals; 612.821
• DOI: 10.1111/jsr.13328
• Languages: English
• ISSNs: 0962-1105

Abstract

Abstract: The orexin receptor antagonist suvorexant was previously reported to significantly improve total sleep time (TST), by 28 min per night versus placebo after 4 weeks, in a sleep laboratory polysomnography (PSG) study of patients with Alzheimer's disease and insomnia. The study included an exploratory evaluation of a consumer‐grade wearable "watch" device for assessing sleep that we report on here. Participants who met diagnostic criteria for both probable Alzheimer's disease dementia and insomnia were randomized to suvorexant 10–20 mg ( N = 142) or placebo ( N = 143) in a double‐blind, 4‐week trial. Patients were provided with a consumer‐grade wearable watch device (Garmin vívosmart ® HR) to be worn continuously. Overnight sleep laboratory PSG was performed on three nights: screening, baseline and Night 29 (last dose). Watch treatment effects were assessed by change‐from‐baseline in watch TST at Week 4 (average TST per night). We also analysed Night 29 data only, with watch data restricted to the PSG recording time. In the 193 participants included in the Week 4 watch analysis (suvorexant = 97, placebo = 96), the suvorexant–placebo difference in watch TST was 4 min ( p = .622). In patients with usable data for both assessments at the baseline and Night 29 PSG (suvorexant = 57, placebo = 50), the watch overestimated TST compared to PSG (e.g., placebo baseline = 412 min for watch and 265 min for PSG) and underestimated change‐from‐baseline treatment effects: the suvorexant–placebo difference was 20 min for watch TST ( p = .405) and 35 min for PSG TST ( p = .057). These findings show that the watch was less sensitive than PSG for evaluating treatment effects on TST.